Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?

ACS Chemical Neuroscience

Volumn 8, Issue 4, 2017, Pages 702-711

  Herrera, Andrea ^a,b   Muñoz, Patricia ^a   Steinbusch, Harry W M ^b   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

alpha synuclein; astrocytes; autophagy dysfunction; endoplasmic reticulum stress; mitochondria dysfunction; Neurodegeneration; neuroinflammation; proteasome dysfunction

Indexed keywords

DOPAMINE; GLUTATHIONE TRANSFERASE M2; NEUROMELANIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); MELANIN;

DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM STRESS; HUMAN; METABOLITE; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; METABOLISM; NERVE DEGENERATION; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; MELANINS; NERVE DEGENERATION; OXIDATION-REDUCTION; PARKINSON DISEASE; PARS COMPACTA;

EID: 85018528188     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.7b00034     Document Type: Review

References (150)

1. Carlsson, A., Lindqvist, M., and Magnusson, T. (1957) 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists Nature 180, 1200 10.1038/1801200a0
2. Segura-Aguilar, J., Muñoz, P., and Paris, I. (2016) Aminochrome as new preclinical model to find new pharmacological treatment that stop the development of Parkinsońs disease Curr. Med. Chem. 23, 346-359 10.2174/0929867323666151223094103
3. Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P. O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., Fisone, G., Jon Stoessl, A., Bourdenx, M., Engeln, M., Navailles, S., De Deurwaerdère, P., Ko, W. K., Simola, N., Morelli, M., Groc, L., Rodriguez, M. C., Gurevich, E. V., Quik, M., Morari, M., Mellone, M., Gardoni, F., Tronci, E., Guehl, D., Tison, F., Crossman, A. R., Kang, U. J., Steece-Collier, K., Fox, S., Carta, M., Angela Cenci, M., and Bézard, E. (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease Prog. Neurobiol. 132, 96-168 10.1016/j.pneurobio.2015.07.002
4. Ko, J. H., Lerner, R. P., and Eidelberg, D. (2015) Effects of levodopa on regional cerebral metabolism and blood flow Mov. Disord. 30, 54-63 10.1002/mds.26041
5. Schaeffer, E., Pilotto, A., and Berg, D. (2014) Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease CNS Drugs 28, 1155-1184 10.1007/s40263-014-0205-z
6. Aosaki, T., Miura, M., Suzuki, T., Nishimura, K., and Masuda, M. (2010) Acetylcholine-dopamine balance hypothesis in the striatum: an update Geriatr. Gerontol. Int. 10, S148-S157 10.1111/j.1447-0594.2010.00588.x
7. Ismayilova, N., Verkhratsky, A., and Dascombe, M. J. (2006) Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats Eur. J. Pharmacol. 545, 134-141 10.1016/j.ejphar.2006.06.076
8. Segura-Aguilar, J. and Kostrzewa, R. M. (2015) Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update Neurotoxic. Res. 27, 328-354 10.1007/s12640-015-9519-y
9. Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O., and Saarma, M. (2016) Current disease modifying approaches to treat Parkinson's disease Cell. Mol. Life Sci. 73, 1365-1379 10.1007/s00018-015-2101-1
10. Park, A. and Stacy, M. (2015) Disease-Modifying Drugs in Parkinson's disease Drugs 75, 2065-2071 10.1007/s40265-015-0497-4
11. Athauda, D. and Foltynie, T. (2015) The ongoing pursuit of neuroprotective therapies in Parkinson disease Nat. Rev. Neurol. 11, 25-40 10.1038/nrneurol.2014.226
12. Segura-Aguilar, J., Paris, I., and Muñoz, P. (2016) The need of a new and more physiological preclinical model for Parkinson's disease Cell. Mol. Life Sci. 73, 1381-2 10.1007/s00018-016-2140-2
13. Segura-Aguilar, J. (2016) New preclinical model are required to discover neuroprotective compound in Parkinson's disease Pharmacol. Res. 10.1016/j.phrs.2016.11.034
14. Segura-Aguilar, J. (2017) Why we cannot translate successful results to new therapies in Parkinsońs disease Clin. Pharmacol. Transl. Med. 1, 6-14
15. Muñoz, P. and Segura-Aguilar, J. (2016) Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease Front. Pharmacol. 7, 179 10.3389/fphar.2016.00179
16. Muñoz, P., Paris, I., and Segura-Aguilar, J. (2016) Commentary: Evaluation of Models of Parkinson's Disease Front. Neurosci. 10, 161 10.3389/fnins.2016.00161
17. Williams, A. (1986) MPTP toxicity: clinical features J. Neural Transm. Suppl. 20, 5-9
18. Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., and Romero-Ramos, M. (2016) Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model J. Neurosci. 36, 9375-90 10.1523/JNEUROSCI.1636-16.2016
19. Lee, J. A., Son, H. J., Kim, J. H., Park, K. D., Shin, N., Kim, H. R., Kim, E. M., Kim, D. J., and Hwang, O. (2016) A novel synthetic isothiocyanate ITC-57 displays antioxidant, anti-inflammatory, and neuroprotective properties in a mouse Parkinson's disease model Free Radical Res. 6, 1-12 10.1080/10715762.2016.1223293
20. Yuan, J., Ren, J., Wang, Y., He, X., and Zhao, Y. (2016) Acteoside Binds to Caspase-3 and Exerts Neuroprotection in the Rotenone Rat Model of Parkinson's Disease PLoS One 11, e0162696 10.1371/journal.pone.0162696
21. Xiao-Feng, L., Wen-Ting, Z., Yuan-Yuan, X., Chong-Fa, L., Lu, Z., Jin-Jun, R., and Wen-Ya, W. (2016) Protective role of 6-Hydroxy-1-H-indazole in an MPTP-induced mouse model of Parkinson's disease Eur. J. Pharmacol. 791, 348-354 10.1016/j.ejphar.2016.08.011
22. Yang, H. J., Gao, Y., Yun, J. Y., Kim, Y. E., Ehm, G., Lee, J. Y., Yoon, M. Y., Lee, Y. S., Kim, H. J., and Jeon, B. (2017) Acupuncture does not protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in a preclinical mouse model of Parkinson's disease NeuroReport 28, 50-55 10.1097/WNR.0000000000000709
23. Afshin-Majd, S., Bashiri, K., Kiasalari, Z., Baluchnejadmojarad, T., Sedaghat, R., and Roghani, M. (2017) Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat Biomed. Pharmacother. 89, 1-9 10.1016/j.biopha.2017.02.007
24. Zhang, Z. N., Zhang, J. S., Xiang, J., Yu, Z. H., Zhang, W., Cai, M., Li, X. T., Wu, T., Li, W. W., and Cai, D. F. (2017) Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study Brain Res. 1655, 104-113 10.1016/j.brainres.2016.11.020
25. Olanow, C. W., Bartus, R. T., Volpicelli-Daley, L. A., and Kordower, J. H. (2015) Trophic factors for Parkinson's disease: To live or let die Mov. Disord. 30, 1715-1724 10.1002/mds.26426
26. Olanow, C. W., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., Jankovic, J., Simpson, R., Watts, R., Guthrie, B., Poston, K., Henderson, J. M., Stern, M., Baltuch, G., Goetz, C. G., Herzog, C., Kordower, J. H., Alterman, R., Lozano, A. M., and Lang, A. E. (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial Ann. Neurol. 78, 248-257 10.1002/ana.24436
27. Hernandez, D. G., Reed, X., and Singleton, A. B. (2016) Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance J. Neurochem. 139, 59-74 10.1111/jnc.13593
28. Kalinderi, K., Bostantjopoulou, S., and Fidani, L. (2016) The genetic background of Parkinson's disease: current progress and future prospects Acta Neurol. Scand. 134, 314-326 10.1111/ane.12563
29. Gan-Or, Z., Dion, P. A., and Rouleau, G. A. (2015) Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease Autophagy 11, 1443-1457 10.1080/15548627.2015.1067364
30. Verstraeten, A., Theuns, J., and Van Broeckhoven, C. (2015) Progress in unraveling the genetic etiology of Parkinson disease in a genomic era Trends Genet. 31, 140-149 10.1016/j.tig.2015.01.004
31. Spatola, M. and Wider, C. (2014) Genetics of Parkinson's disease: the yield Parkinsonism Relat. Disord. 20, S35-S38 10.1016/S1353-8020(13)70011-7
32. Lin, M. K. and Farrer, M. J. (2014) Genetics and genomics of Parkinson's disease Genome Med. 6, 48 10.1186/gm566
33. Kienzl, E., Jellinger, K., Stachelberger, H., and Linert, W. (1999) Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? Life Sci. 65, 1973-1976 10.1016/S0024-3205(99)00458-0
34. Linert, W., Herlinger, E., Jameson, R. F., Kienzl, l.E., Jellinger, K., and Youdim, M. B. (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease Biochim. Biophys. Acta, Mol. Basis Dis. 1316, 160-168 10.1016/0925-4439(96)00020-8
35. Kim, E. Y., Koh, J. Y., Kim, Y. H., Sohn, S., Joe, E., and Gwag, B. J. (1999) Zn2+ entry produces oxidative neuronal necrosis in cortical cell cultures Eur. J. Neurosci. 11, 327-334 10.1046/j.1460-9568.1999.00437.x
36. Levin, J., Högen, T., Hillmer, A. S., Bader, B., Schmidt, F., Kamp, F., Kretzschmar, H. A., Bötzel, K., and Giese, A. (2011) Generation of ferric iron links oxidative stress to α-synuclein oligomer formation J. Parkinson's Dis. 1, 205-216 10.3233/JPD-2011-11040
37. Mullin, S. and Schapira, A. (2013) α-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease Mol. Neurobiol. 47, 587-597 10.1007/s12035-013-8394-x
38. Yong-Kee, C. J., Sidorova, E., Hanif, A., Perera, G., and Nash, J. E. (2012) Mitochondrial dysfunction precedes other sub-cellular abnormalities in an in vitro model linked with cell death in Parkinson's disease Neurotoxic. Res. 21, 185-194 10.1007/s12640-011-9259-6
39. Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., and Lang, A. E. (2013) α-Synuclein oligomers and clinical implications for Parkinson disease Ann. Neurol. 73, 155-169 10.1002/ana.23746
40. Ebrahimi-Fakhari, D., Wahlster, L., and McLean, P. J. (2012) Protein degradation pathways in Parkinson's disease: curse or blessing Acta Neuropathol. 124, 153-172 10.1007/s00401-012-1004-6
41. Franco-Iborra, S., Vila, M., and Perier, C. (2016) The Parkinson Disease Mitochondrial Hypothesis: Where Are We at? Neuroscientist 22, 266-277 10.1177/1073858415574600
42. Zanellati, M. C., Monti, V., Barzaghi, C., Reale, C., Nardocci, N., Albanese, A., Valente, E. M., Ghezzi, D., and Garavaglia, B. (2015) Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts Front. Genet. 6, 78 10.3389/fgene.2015.00078
43. Caito, S. W. and Aschner, M. (2015) Mitochondrial Redox Dysfunction and Environmental Exposures Antioxid. Redox Signaling 23, 578-595 10.1089/ars.2015.6289
44. Morris, G. and Berk, M. (2015) The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders BMC Med. 13, 68 10.1186/s12916-015-0310-y
45. Zaltieri, M., Longhena, F., Pizzi, M., Missale, C., Spano, P., and Bellucci, A. (2015) Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? Parkinson's Dis. 2015, 108029 10.1155/2015/108029
46. Martinez-Vicente, M. and Vila, M. (2013) Alpha-synuclein and protein degradation pathways in Parkinson's disease: A pathological feed-back loop Exp. Neurol. 247, 308-313 10.1016/j.expneurol.2013.03.005
47. Hauser, D. N. and Hastings, T. G. (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism Neurobiol. Dis. 51, 35-42 10.1016/j.nbd.2012.10.011
48. Mercado, G., Valdés, P., and Hetz, C. (2013) An ERcentric view of Parkinson's disease Trends Mol. Med. 19, 165-175 10.1016/j.molmed.2012.12.005
49. Rohn, T. T. (2012) Targeting alpha-synuclein for the treatment of Parkinson's disease. CNS Neurol CNS Neurol. Disord.: Drug Targets 11, 174-179 10.2174/187152712800269678
50. Taylor, J. M., Main, B. S., and Crack, P. J. (2013) Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson's disease Neurochem. Int. 62, 803-819 10.1016/j.neuint.2012.12.016
51. Exner, N., Lutz, A. K., Haass, C., and Winklhofer, K. F. (2012) Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences EMBO J. 31, 3038-3062 10.1038/emboj.2012.170
52. Hang, L., Thundyil, J., and Lim, K. L. (2015) Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection Ann. N. Y. Acad. Sci. 1350, 37-47 10.1111/nyas.12820
53. Moon, H. E. and Paek, S. H. (2015) Mitochondrial Dysfunction in Parkinson's Disease Exp. Neurobiol. 24, 103-16 10.5607/en.2015.24.2.103
54. Moors, T., Paciotti, S., Chiasserini, D., Calabresi, P., Parnetti, L., Beccari, T., and van de Berg, W. D. (2016) Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease Mov. Disord. 31, 791-801 10.1002/mds.26562
55. Vos, M., Verstreken, P., and Klein, C. (2015) Stimulation of electron transport as potential novel therapy in Parkinson's disease with mitochondrial dysfunction Biochem. Soc. Trans. 43, 275-279 10.1042/BST20140325
56. Yamano, K., Matsuda, N., and Tanaka, K. (2016) The ubiquitin signal and autophagy: an orchestrated dance leading to mitochondrial degradation EMBO Rep. 17, 300-316 10.15252/embr.201541486
57. Xilouri, M., Brekk, O. R., and Stefanis, L. (2016) Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies Mov. Disord. 31, 178-192 10.1002/mds.26477
58. Joers, V., Tansey, M. G., Mulas, G., and Carta, A. R. (2016) Microglial phenotypes in Parkinson's disease and animal models of the disease Prog. Neurobiol. 10.1016/j.pneurobio.2016.04.006
59. Mercado, G., Castillo, V., Soto, P., and Sidhu, A. (2016) ER stress and Parkinson disease: Pathological inputs that converge into the secretory pathway Brain Res. 1648, 626-632 10.1016/j.brainres.2016.04.042
60. Cartier, E. A., Parra, L. A., Baust, T. B., Quiroz, M., Salazar, G., Faundez, V., Egaña, L., and Torres, G. E. (2010) A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles J. Biol. Chem. 285, 1957-1966 10.1074/jbc.M109.054510
61. Segura-Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., and Zucca, F. A. (2014) Protective and toxic roles of dopamine in Parkinson's disease J. Neurochem. 129, 898-915 10.1111/jnc.12686
62. Asanuma, M., Miyazaki, I., Murakami, S., Diaz-Corrales, F. J., and Ogawa, N. (2014) Striatal astrocytes act as a reservoir for L-DOPA PLoS One 9, e106362 10.1371/journal.pone.0106362
63. Inyushin, M. Y., Huertas, A., Kucheryavykh, Y. V., Kucheryavykh, L. Y., Tsydzik, V., Sanabria, P., Eaton, M. J., Skatchkov, S. N., Rojas, L. V., and Wessinger, W. D. (2012) L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain Parkinson's Dis. 2012, 321406 10.1155/2012/321406
64. Zecca, L., Fariello, R., Riederer, P., Sulzer, D., Gatti, A., and Tampellini, D. (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease FEBS Lett. 510, 216-20 10.1016/S0014-5793(01)03269-0
65. Bisaglia, M., Mammi, S., and Bubacco, L. (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein J. Biol. Chem. 282, 15597-15605 10.1074/jbc.M610893200
66. Graham, D. G. (1984) Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinsońs disease NeuroToxicology 5, 83-96
67. Segura-Aguilar, J. and Lind, C. (1989) On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase Chem.-Biol. Interact. 72, 309-324 10.1016/0009-2797(89)90006-9
68. Tse, D. C. S., McCreery, R. L., and Adams, R. N. (1976) Potential oxidative pathways of brain catecholamines J. Med. Chem. 19, 37-34 10.1021/jm00223a008
69. Van Laar, V. S., Mishizen, A. J., Cascio, M., and Hastings, T. G. (2009) Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells Neurobiol. Dis. 34, 487-500 10.1016/j.nbd.2009.03.004
70. LaVoie, M., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., and Selkoe, D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin Nat. Med. 11, 1214-1221 10.1038/nm1314
71. Whitehead, R. E., Ferrer, J. V., Javitch, J. A., and Justice, J. B. (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter J. Neurochem. 76, 1242-1251 10.1046/j.1471-4159.2001.00125.x
72. Xu, Y., Stokes, A. H., Roskoski, R., Jr., and Vrana, K. E. (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase J. Neurosci. Res. 54, 691-697 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F
73. Arriagada, C., Paris, I., Sanchez de las Matas, M. J., Martinez-Alvarado, P., Cardenas, S., Castañeda, P., Graumann, R., Perez-Pastene, C., Olea-Azar, C., Couve, E., Herrero, M. T., Caviedes, P., and Segura-Aguilar, J. (2004) On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation Neurobiol. Dis. 16, 468-77 10.1016/j.nbd.2004.03.014
74. Fuentes, P., Paris, I., Nassif, M., Caviedes, P., and Segura-Aguilar, J. (2007) Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line an experimental cell model for dopamine toxicity studies Chem. Res. Toxicol. 20, 776-783 10.1021/tx600325u
75. Paris, I., Muñoz, P., Huenchuguala, S., Couve, E., Sanders, L. H., Greenamyre, J. T., Caviedes, P., and Segura-Aguilar, J. (2011) Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line Toxicol. Sci. 121, 376-388 10.1093/toxsci/kfr060
76. Aguirre, P., Urrutia, P., Tapia, V., Villa, M., Paris, I., Segura- Aguilar, J., and Nuñez, M. T. (2012) The dopamine metabolite aminochromeinhibits mitochondrial complex I and modifies the expression of iron transportersDMT1and FPN1 BioMetals 25, 795-803 10.1007/s10534-012-9525-y
77. Muñoz, P., Paris, I., Sanders, L. H., Greenamyre, J. T., and Segura-Aguilar, J. (2012) Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity Biochim. Biophys. Acta, Mol. Basis Dis. 1822, 1125-1136 10.1016/j.bbadis.2012.03.010
78. Herrera, A., Muñoz, P., Paris, I., Díaz-Veliz, G., Mora, S., Inzunza, J., Hultenby, K., Cardenas, C., Jaña, F., Raisman-Vozari, R., Gysling, K., Abarca, J., Steinbusch, H. W., and Segura-Aguilar, J. (2016) Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease Cell. Mol. Life Sci. 73, 3583-3597 10.1007/s00018-016-2182-5
79. Muñoz, P., Cardenas, S., Huenchuguala, S., Briceño, A., Couve, E., Paris, I., and Segura-Aguilar, J. (2015) DT Diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity Toxicol. Sci. 145, 37-47 10.1093/toxsci/kfv016
80. Muñoz, P., Huenchuguala, S., Paris, I., and Segura-Aguilar, J. (2012) Dopamine oxidation and autophagy Parkinson's Dis. 2012, 920953 10.1155/2012/920953
81. Huenchuguala, S., Muñoz, P., Zavala, P., Villa, M., Cuevas, C., Ahumada, U., Graumann, R., Nore, B. F., Couve, E., Mannervik, B., Paris, I., and Segura-Aguilar, J. (2014) Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction Autophagy 10, 618-630 10.4161/auto.27720
82. Zafar, K. S., Siegel, D., and Ross, D. (2006) A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4- dihydroxyphenylacetic acid in proteasomal inhibition Mol. Pharmacol. 70, 1079-1086 10.1124/mol.106.024703
83. Xiong, R., Siegel, D., and Ross, D. (2014) Quinone-induced protein handling changes: implications for major protein handling systems in quinone-mediated toxicity Toxicol. Appl. Pharmacol. 280, 285-295 10.1016/j.taap.2014.08.014
84. Paris, I., Perez-Pastene, C., Cardenas, S., Iturriaga-Vasquez, P., Muñoz, P., Couve, E., Caviedes, P., and Segura-Aguilar, J. (2010) Aminochrome induces disruption of actin, alpha- and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line Neurotoxic. Res. 18, 82-92 10.1007/s12640-009-9148-4
85. Briceño, A., Muñoz, P., Brito, P., Huenchuguala, S., Segura-Aguilar, J., and Paris, I. B. (2016) Aminochrome toxicity is mediated by inhibition of microtubules polymerization through the formation of adducts with tubulin Neurotoxic. Res. 29, 381-393 10.1007/s12640-015-9560-x
86. Napolitano, A., Manini, P., and d'Ischia, M. (2011) Oxidation chemistry of catecholamines and neuronal degeneration: an update Curr. Med. Chem. 18, 1832-45 10.2174/092986711795496863
87. Bisaglia, M., Soriano, M. E., Arduini, I., Mammi, S., and Bubacco, L. (2010) Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease Biochim. Biophys. Acta, Mol. Basis Dis. 1802, 699-706 10.1016/j.bbadis.2010.06.006
88. Pezzella, A., Crescenzi, O., Natangelo, A., Panzella, L., Napolitano, A., Navaratnam, S., Edge, R., Land, E. J., Barone, V., and d'Ischia, M. (2007) Chemical, pulse radiolysis and density functional studies of a new, labile 5,6-indolequinone and its semiquinone J. Org. Chem. 72, 1595-603 10.1021/jo0615807
89. Zajac, G. W., Gallas, J. M., Cheng, J., Eisner, M., Moss, S. C., and Alvarado-Swaisgood, A. E. (1994) The fundamental unit of synthetic melanin: a verification by tunneling microscopy of X-ray scattering results Biochim. Biophys. Acta, Gen. Subj. 1199, 271-278 10.1016/0304-4165(94)90006-X
90. Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., and Lee, V. M. (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations J. Biol. Chem. 280, 21212-21219 10.1074/jbc.M412621200
91. Linsenbardt, A. J., Breckenridge, J. M., Wilken, G. H., and Macarthur, H. (2012) Dopaminochrome induces caspase-independent apoptosis in the mesencephalic cell line, MN9D J. Neurochem. 122 (1) 175-84 10.1111/j.1471-4159.2012.07756.x
92. Linsenbardt, A. J., Wilken, G. H., Westfall, T. C., and Macarthur, H. (2009) Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress NeuroToxicology 30, 1030-1035 10.1016/j.neuro.2009.07.006
93. Zoccarato, F., Toscano, P., and Alexandre, A. (2005) Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease J. Biol. Chem. 280, 15587-15594 10.1074/jbc.M500657200
94. Galzigna, L., Schiappelli, M. P., Rigo, A., and Scarpa, M. (1999) A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine Biochim. Biophys. Acta, Gen. Subj. 1427, 329-336 10.1016/S0304-4165(99)00037-9
95. Galzigna, L., Zanatta, L., and Esposito, N. (1999) Toxicity of dopamine and dopaminochrome on cultured cells Neurotoxic. Res. 1, 149-152 10.1007/BF03033278
96. Ochs, S. D., Westfall, T. C., and Macarthur, H. (2005) The separation and quantification of aminochromes using high-pressure liquid chromatography with electrochemical detection J. Neurosci. Methods 142, 201-208 10.1016/j.jneumeth.2004.08.010
97. Touchette, J. C., Breckenridge, J. M., Wilken, G. H., and Macarthur, H. (2016) Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons Neurosci. Lett. 612, 178-184 10.1016/j.neulet.2015.12.028
98. Lozano, J., Muñoz, P., Nore, B. F., Ledoux, S., and Segura-Aguilar, J. (2010) Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity Chem. Res. Toxicol. 23, 1492-1496 10.1021/tx100182a
99. Segura-Aguilar, J., Baez, S., Widersten, M., Welch, C. J., and Mannervik, B. (1997) Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome J. Biol. Chem. 272, 5727-5731 10.1074/jbc.272.9.5727
100. Baez, S., Segura-Aguilar, J., Widersten, M., Johansson, A. S., and Mannervik, B. (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes Biochem. J. 324, 25-28 10.1042/bj3240025
101. Ma, Q. (2013) Role of nrf2 in oxidative stress and toxicity Annu. Rev. Pharmacol. Toxicol. 53, 401-26 10.1146/annurev-pharmtox-011112-140320
102. Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Annu. Rev. Pharmacol. Toxicol. 47, 89-116 10.1146/annurev.pharmtox.46.120604.141046
103. Nguyen, T., Sherratt, P. J., and Pickett, C. B. (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element Annu. Rev. Pharmacol. Toxicol. 43, 233-260 10.1146/annurev.pharmtox.43.100901.140229
104. Zhang, Y., Hou, Y., Liu, C., Li, Y., Guo, W., Wu, J. L., Xu, D., You, X., Pan, Y., and Chen, Y. (2016) Identification of an adaptor protein that facilitates Nrf2-Keap1 complex formation and modulates antioxidant response Free Radical Biol. Med. 97, 38-49 10.1016/j.freeradbiomed.2016.05.017
105. Chen, S., Zhang, Z., Qing, T., Ren, Z., Yu, D., Couch, L., Ning, B., Mei, N., Shi, L., Tolleson, W. H., and Guo, L. (2017) Activation of the Nrf2 signaling pathway in usnic acid-induced toxicity in HepG2 cells Arch. Toxicol. 91, 1293 10.1007/s00204-016-1775-y
106. Esmaeili, M. A. and Alilou, M. (2014) Naringenin attenuates CCl4 -induced hepatic inflammation by the activation of an Nrf2-mediated pathway in rats Clin. Exp. Pharmacol. Physiol. 41, 416-422 10.1111/1440-1681.12230
107. Gao, S., Duan, X., Wang, X., Dong, D., Liu, D., Li, X., Sun, G., and Li, B. (2013) Curcumin attenuates arsenic-induced hepatic injuries and oxidative stress in experimental mice through activation of Nrf2 pathway, promotion of arsenic methylation and urinary excretion Food Chem. Toxicol. 59, 739-47 10.1016/j.fct.2013.07.032
108. Jin, W., Ming, X., Hou, X., Zhu, T., Yuan, B., Wang, J., Ni, H., Jiang, J., Wang, H., and Liang, W. (2014) Protective effects of erythropoietin in traumatic spinal cord injury by inducing the Nrf2 signaling pathway activation J. Trauma Acute Care Surg. 76, 1228-1234 10.1097/TA.0000000000000211
109. Wang, D., Wang, Y., Wan, X., Yang, C. S., and Zhang, J. (2015) Green tea polyphenol (-)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway Toxicol. Appl. Pharmacol. 283, 65-74 10.1016/j.taap.2014.12.018
110. Lee, M. S., Lee, B., Park, K. E., Utsuki, T., Shin, T., Oh, C. W., and Kim, H. R. (2015) Dieckol enhances the expression of antioxidant and detoxifying enzymes by the activation of Nrf2-MAPK signalling pathway in HepG2 cells Food Chem. 174, 538-546 10.1016/j.foodchem.2014.11.090
111. Deng, Y., Zhu, J., Mi, C., Xu, B., Jiao, C., Li, Y., Xu, D., Liu, W., and Xu, Z. (2015) Melatonin antagonizes Mn-induced oxidative injury through the activation of keap1-Nrf2-ARE signaling pathway in the striatum of mice Neurotoxic. Res. 27, 156-71 10.1007/s12640-014-9489-5
112. Byun, H. G. and Lee, J. K. (2015) Chlorella ethanol extract induced phase II enzyme through NFE2L2 (nuclear factor [erythroid-derived] 2-like 2, NRF2) activation and protected ethanol-induced hepatoxicity J. Med. Food 18, 182-189 10.1089/jmf.2014.3159
113. Das, L. and Vinayak, M. (2015) Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer PLoS One 10, e0124000 10.1371/journal.pone.0124000
114. Duan, X., Li, J., Zhang, Y., Li, W., Zhao, L., Nie, H., Sun, G., and Li, B. (2015) Activation of NRF2 pathway in spleen, thymus as well as peripheral blood mononuclear cells by acute arsenic exposure in mice Int. Immunopharmacol. 28, 1059-67 10.1016/j.intimp.2015.08.025
115. Shoji, M., Arakaki, Y., Esumi, T., Kohnomi, S., Yamamoto, C., Suzuki, Y., Takahashi, E., Konishi, S., Kido, H., and Kuzuhara, T. (2015) Bakuchiol Is a Phenolic Isoprenoid with Novel Enantiomer-selective Anti-influenza A Virus Activity Involving Nrf2 Activation J. Biol. Chem. 290, 28001-28017 10.1074/jbc.M115.669465
116. Li, H., He, H., Wang, Z., Cai, J., Sun, B., Wu, Q., Zhang, Y., Zhou, G., and Yang, L. (2016) Rice protein suppresses ROS generation and stimulates antioxidant gene expression via Nrf2 activation in adult rats Gene 585, 256-64 10.1016/j.gene.2016.03.052
117. Zhang, Y., Duan, X., Li, J., Zhao, S., Li, W., Zhao, L., Li, W., Nie, H., Sun, G., and Li, B. (2016) Inorganic Arsenic Induces NRF2-Regulated Antioxidant Defenses in Both Cerebral Cortex and Hippocampus in Vivo Neurochem. Res. 41, 2119-28 10.1007/s11064-016-1927-8
118. Williams, L. M., Lago, B. A., McArthur, A. G., Raphenya, A. R., Pray, N., Saleem, N., Salas, S., Paulson, K., Mangar, R. S., Liu, Y., Vo, A. H., and Shavit, J. A. (2016) The transcription factor, Nuclear factor, erythroid 2 (Nfe2), is a regulator of the oxidative stress response during Danio rerio development Aquat. Toxicol. 180, 141-154 10.1016/j.aquatox.2016.09.019
119. Siebert, A., Desai, V., Chandrasekaran, K., Fiskum, G., and Jafri, M. S. (2009) Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures J. Neurosci. Res. 87, 1659-1669 10.1002/jnr.21975
120. Liang, C. L., Nelson, O., Yazdani, U., Pasbakhsh, P., and German, D. C. (2004) Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons J. Comp. Neurol. 473, 97-106 10.1002/cne.20098
121. Pifl, C., Rajput, A., Reither, H., Blesa, J., Cavada, C., Obeso, J. A., Rajput, A. H., and Hornykiewicz, O. (2014) Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum J. Neurosci. 34, 8210-8218 10.1523/JNEUROSCI.5456-13.2014
122. Schultzberg, M., Segura-Aguilar, J., and Lind, C. (1988) Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies Neuroscience 27, 763-76 10.1016/0306-4522(88)90181-9
123. Dagnino-Subiabre, A., Cassels, B. K., Baez, S., Johansson, A. S., Mannervik, B., and Segura-Aguilar, J. (2000) Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones Biochem. Biophys. Res. Commun. 274, 32-6 10.1006/bbrc.2000.3087
124. Cheng, F. C., Kuo, J. S., Chia, L. G., and Dryhurst, G. (1996) Elevated 5-Scysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid incerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease J. Neural. Transm. 103, 433-446 10.1007/BF01276419
125. Carstam, R., Brinck, C., Hindemith-Augustsson, A., Rorsman, H., and Rosengren, E. (1991) The neuromelanin of the human substantia nigra Biochim. Biophys. Acta, Mol. Basis Dis. 1097, 152-160 10.1016/0925-4439(91)90100-N
126. Rosengren, E., Linder-Eliasson, E., and Carlsson, A. (1985) Detection of 5-S-cysteinyldopamine in 559 human brain J. Neural. Transm. 63, 247-253 10.1007/BF01252029
127. Cuevas, C., Huenchuguala, S., Muñoz, P., Villa, M., Paris, I., Mannervik, B., and Segura-Aguilar, J. (2015) Glutathione Transferase-M2-2 Secreted from Glioblastoma Cell Protects SH-SY5Y Cells from Aminochrome Neurotoxicity Neurotoxic. Res. 27, 217-228 10.1007/s12640-014-9500-1
128. Segura-Aguilar, J. (2015) A new mechanism for protection of dopaminergic neurons mediated by astrocytes Neural Regener. Res. 10, 1225-1227 10.4103/1673-5374.162750
129. Segura-Aguilar, J. Aminochrome as preclinical model for Parkinson's disease. Oncotarget 2017, in press.
130. Huenchuguala, S., Muñoz, P., Graumann, R., Paris, I., and Segura-Aguilar, J. (2016) DT-diaphorase protects astrocytes from aminochrome-induced toxicity NeuroToxicology 55, 10-12 10.1016/j.neuro.2016.04.014
131. Prajapati, S. K., Garabadu, D., and Krishnamurthy, S. (2017) Coenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats Neurotoxic. Res. 10.1007/s12640-016-9693-6
132. Elkon, H., Melamed, E., and Offen, D. (2004) Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease J. Mol. Neurosci. 24, 387-400 10.1385/JMN:24:3:387
133. Zhang, J., Cai, Q., Jiang, M., Liu, Y., Gu, H., Guo, J., Sun, H., Fang, J., and Jin, L. (2017) Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition Exp. Gerontol. 89, 45-56 10.1016/j.exger.2017.01.010
134. In, S., Hong, C. W., Choi, B., Jang, B. G., and Kim, M. J. (2016) Inhibition of Mitochondrial Clearance and Cu/Zn-SOD Activity Enhance 6-Hydroxydopamine-Induced Neuronal Apoptosis Mol. Neurobiol. 53, 777-791 10.1007/s12035-014-9087-9
135. Baluchnejadmojarad, T., Mansouri, M., Ghalami, J., Mokhtari, Z., and Roghani, M. (2017) Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis, and oxidative stress Biomed. Pharmacother. 88, 754-761 10.1016/j.biopha.2017.01.123
136. Avagliano, C., Russo, R., De Caro, C., Cristiano, C., La Rana, G., Piegari, G., Paciello, O., Citraro, R., Russo, E., De Sarro, G., Meli, R., Mattace Raso, G., and Calignano, A. (2016) Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence Pharmacol. Res. 113, 276-289 10.1016/j.phrs.2016.09.004
137. Nataraj, J., Manivasagam, T., Thenmozhi, A. J., and Essa, M. M. (2016) Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress Nutr. Neurosci. 19, 237-246 10.1179/1476830515Y.0000000010
138. Bové, J., Martínez-Vicente, M., Dehay, B., Perier, C., Recasens, A., Bombrun, A., Antonsson, B., and Vila, M. (2014) BAX channel activity mediates lysosomal disruption linked to Parkinson disease Autophagy 10, 889-900 10.4161/auto.28286
139. Guo, H., Shi, F., Li, M., Liu, Q., Yu, B., and Hu, L. (2015) Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system BMC Complementary Altern. Med. 15, 151 10.1186/s12906-015-0675-7
140. Cheng, Y. F., Zhu, G. Q., Wang, M., Cheng, H., Zhou, A., Wang, N., Fang, N., Wang, X. C., Xiao, X. Q., Chen, Z. W., and Li, Q. L. (2009) Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis Neurosci. Res. 63, 52-58 10.1016/j.neures.2008.10.009
141. Machado, V., Zöller, T., Attaai, A., and Spittau, B. (2016) Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice Int. J. Mol. Sci. 17 (2) 151 10.3390/ijms17020151
142. Tsujii, S., Ishisaka, M., Shimazawa, M., Hashizume, T., and Hara, H. (2015) Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo Eur. J. Pharmacol. 746, 301-307 10.1016/j.ejphar.2014.09.023
143. Yu, J., Xu, H., Shen, X., and Jiang, H. (2016) Ghrelin protects MES23.5 cells against rotenone via inhibiting mitochondrial dysfunction and apoptosis Neuropeptides 56, 69-74 10.1016/j.npep.2015.09.011
144. Chou, A. P., Li, S., Fitzmaurice, A. G., and Bronstein, J. M. (2010) Mechanisms of rotenone-induced proteasome inhibition NeuroToxicology 31, 367-372 10.1016/j.neuro.2010.04.006
145. Wu, F., Xu, H. D., Guan, J. J., Hou, Y. S., Gu, J. H., Zhen, X. C., and Qin, Z. H. (2015) Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease Neuroscience 284, 900-911 10.1016/j.neuroscience.2014.11.004
146. Dhanalakshmi, C., Janakiraman, U., Manivasagam, T., Justin Thenmozhi, A., Essa, M. M., Kalandar, A., Khan, M. A., and Guillemin, G. J. (2016) Vanillin Attenuated Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and Apoptosis Against Rotenone Induced Rat Model of Parkinson's Disease Neurochem. Res. 41, 1899-1910 10.1007/s11064-016-1901-5
147. Ojha, S., Javed, H., Azimullah, S., Abul Khair, S. B., and Haque, M. E. (2016) Glycyrrhizic acid Attenuates Neuroinflammation and Oxidative Stress in Rotenone Model of Parkinson's Disease Neurotoxic. Res. 29, 275-287 10.1007/s12640-015-9579-z
148. Su, L. Y., Li, H., Lv, L., Feng, Y. M., Li, G. D., Luo, R., Zhou, H. J., Lei, X. G., Ma, L., Li, J. L., Xu, L., Hu, X. T., and Yao, Y. G. (2015) Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation Autophagy 11, 1745-1759 10.1080/15548627.2015.1082020
149. Ren, R., Shi, C., Cao, J., Sun, Y., Zhao, X., Guo, Y., Wang, C., Lei, H., Jiang, H., Ablat, N., Xu, J., Li, W., Ma, Y., Qi, X., Ye, M., Pu, X., and Han, H. (2016) Neuroprotective Effects of A Standardized Flavonoid Extract of Safflower Against Neurotoxin-Induced Cellular and Animal Models of Parkinson's Disease Sci. Rep. 6, 22135 10.1038/srep22135
150. Sharrad, D. F., Chen, B. N., Gai, W. P., Vaikath, N., El-Agnaf, O. M., and Brookes, S. J. (2016) Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α-synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum Neurogastroenterol. Motil. 10.1111/nmo.12985